NeuroPace, Inc. NPCE
- Market cap
- $479.5M
- P/E
- 0.0×
Follow NPCE
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 8.29 | 1.22 | 1.38 | 5.45 | 7.56 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 27.38 | 12.06 | 10.32 | 18.15 | 18.98 |
High Price
|
|||
| — | — | — | — | 152 | 166 | 167 | 171 | 184 | 209 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 37 | 41 | 45 | 46 | 65 | 80 | 100 |
Revenue
|
|||
| — | — | — | 71.58% | 73.59% | 74.00% | 71.38% | 73.56% | 73.94% | 77.23% |
Gross Margin
|
|||
| — | — | — | (30) | (24) | (36) | (47) | (33) | (27) | (21) |
EBT
|
|||
| — | — | — | (81.07%) | (59.02%) | (79.85%) | (103.43%) | (50.38%) | (33.97%) | (21.47%) |
EBT Margin
|
|||
| — | 0 | — | (30) | (24) | (36) | (47) | (33) | (27) | (21) |
Net Income
|
|||
| — | — | — | 3 | 4 | 1 | 1 | 0 | 2 | 2 |
Depreciation
|
|||
| — | — | — | 183.12 | 200.67 | 2.72 | 1.85 | 2.53 | 2.74 | 3.06 |
Revenue/Sh
|
|||
| — | — | — | (148.44) | (118.43) | (2.17) | (1.91) | (1.27) | (0.93) | (0.66) |
Earnings/Sh
|
|||
| — | — | — | (123.95) | (105.41) | (1.48) | (1.50) | (0.76) | (0.62) | (0.34) |
Cash Flow/Sh
|
|||
| — | — | — | (2.30) | (0.30) | (0.02) | (0.02) | (0.01) | (0.01) | (0.01) |
Capex/Sh
|
|||
| — | — | — | (126.25) | (105.71) | (1.50) | (1.52) | (0.77) | (0.63) | (0.35) |
Free CF/Sh
|
|||
| — | — | — | (640.66) | (721.13) | 4.43 | 1.41 | 0.80 | 0.28 | 0.58 |
Book Value/Sh
|
|||
| — | — | — | 0 | 0 | 17 | 25 | 26 | 29 | 33 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 0.16 | 0.16 | 3.71 | 0.78 | 3.86 | 4.08 | 5.05 |
PS Ratio
|
|||
| — | — | — | 0.00 | 0.00 | 2.28 | 1.02 | 12.24 | 40.67 | 26.55 |
PB Ratio
|
|||
| — | — | — | 0.69 | 0.69 | 2.33 | 0.27 | 3.74 | 4.18 | 5.05 |
EV/Sales
|
|||
| — | — | — | (1.39) | (1.39) | (4.22) | (0.33) | (12.32) | (18.31) | (44.51) |
EV/FCF
|
|||
| — | — | — | (25) | (22) | (25) | (37) | (20) | (18) | (11) |
Op' Cash Flow
|
|||
| — | — | — | 0 | 0 | 0 | (1) | 0 | 0 | 0 |
Capex
|
|||
| — | — | — | (25) | (22) | (25) | (37) | (20) | (18) | (11) |
FCF
|
|||
| — | — | — | (55) | 45 | 124 | 87 | 76 | 66 | 76 |
Working Cap'
|
|||
| — | — | — | 44 | 53 | 50 | 54 | 57 | 60 | 59 |
Total Debt
|
|||
| — | — | — | 39 | 15 | (66) | (23) | (9) | 7 | (2) |
Net Debt
|
|||
| — | — | — | (129) | (148) | 74 | 35 | 21 | 8 | 19 |
Sh' Equity
|
|||
| — | — | — | (284.17%) | (63.02%) | (38.08%) | (38.02%) | (29.72%) | (26.83%) | (21.44%) |
ROA
|
|||
| — | — | — | 0.00% | 0.00% | (191.03%) | (217.99%) | (152.27%) | (91.62%) | (60.58%) |
ROIC
|
|||
| — | — | — | 21.63% | 17.52% | 97.08% | (86.96%) | (118.91%) | (189.35%) | (158.74%) |
ROE
|
|||
NeuroPace, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SGHT Sight Sciences, Inc. | $478.2M | 0.0× | Compare |
| PACB Pacific Biosciences of California, Inc. | $484.9M | 0.0× | Compare |
| MASS 908 Devices Inc. | $492.7M | 0.0× | Compare |
| CLPT ClearPoint Neuro, Inc. | $445.7M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TCMD Tactile Systems Technology, Inc. | $518.5M | 20.7× | Compare |
| CERS Cerus Corporation | $524.0M | 0.0× | Compare |
| BWAY Brainsway Ltd. Sponsored ADR | $531.6M | 28.9× | Compare |
| SENS Senseonics Holdings, Inc. | $546.7M | 0.0× | Compare |
NeuroPace, Inc. (NPCE) key facts
- NeuroPace, Inc. (NPCE) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- NeuroPace, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.0 million, up 25.1% from fiscal 2024.
- NeuroPace, Inc. reported a net loss of $21.5 million, or a loss of $0.66 per share, for fiscal 2025.
- As of September 25, 2026, NPCE traded at $14.06, a market capitalization of $479.5 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.7× sales.
- Return on equity was −158.7% and debt-to-equity 4.97.
NeuroPace, Inc. (NPCE) Latest News
18 Aug
NeuroPace Inc reported strong RNS system growth and launched AI features in its Q2 2026 earnings call, offsetting other headwinds. Strong RNS growth plus AI launch signals major strategic progress that can significantly shift NeuroPace trajectory and investor views.
17 Aug
NeuroPace encounters FDA setback causing IGE delay that threatens its growth trajectory and market expansion. FDA delay on IGE directly blocks NeuroPace product approval and revenue ramp.
12 Aug
NeuroPace Q2 earnings beat estimates on RNS growth and company raised 2026 revenue view. Earnings beat plus raised 2026 guidance signals stronger growth trajectory and investor sentiment for NeuroPace.
NeuroPace, Inc. summarized its Q2 2026 earnings call covering financial results and company updates. Quarterly earnings updates typically influence near-term sentiment and operations without major strategic shifts.
11 Aug
NeuroPace reported second quarter 2026 financial results and raised 2026 revenue guidance. Raised revenue guidance signals stronger expected performance and can positively influence stock trajectory.
NeuroPace Q2 revenue grew with higher RNS system implants. Company narrowed losses, raised full-year guidance, and advanced pipeline for new epilepsy indications while expanding commercial reach. Q2 earnings and raised guidance deliver moderate financial and operational updates that influence near-term sentiment but do not signal transformative shifts.
28 Jul
NeuroPace received FDA guidance on its PMA supplement to expand indications into idiopathic generalized epilepsy. FDA guidance advances regulatory path for broader epilepsy market access and revenue potential.
NeuroPace's FDA bid to expand epilepsy treatment use has stalled after the agency requested additional data. FDA delay on expanded epilepsy indication postpones potential new revenue streams and market reach for NeuroPace.
27 Jun
NeuroPace, Inc. (NPCE) has obtained FDA approval for its ECoG Assistant™ product. FDA approval of ECoG Assistant™ enables new revenue streams and strengthens NeuroPace's market position in epilepsy treatment.
10 Jun
NeuroPace (NPCE) receives a buy recommendation for immediate portfolio addition based on its growth prospects and market positioning. Stock recommendation may lift short-term sentiment and trading interest without altering core operations or fundamentals.
2 Jun
NeuroPace, Inc. (NPCE) receives FDA approval for its AI-powered ECoG assistant for epilepsy. FDA approval of new AI device strengthens NPCE product portfolio and market position in epilepsy treatment.
29 May
NeuroPace receives FDA approval for ECoG Assistant, advancing its AI-driven epilepsy care technology. FDA approval of ECoG Assistant introduces a key AI product that strengthens NeuroPace's market position in epilepsy treatment.
27 May
NeuroPace's NPCE stock faces 2026 outlook questions after DIXI exit and margin lift. DIXI exit and margin lift represent strategic shifts likely to alter NeuroPace trajectory and investor views.
NeuroPace advances AI integration into its epilepsy devices to drive next-generation treatment precision and patient outcomes. AI-driven platform upgrades signal major product innovation that can materially lift adoption and competitive positioning.
14 May
NeuroPace (NPCE) Q1 2026 earnings call transcript details financial results, operational updates, and forward guidance. Q1 2026 earnings transcript provides key financial metrics, growth updates, and strategic insights likely to impact NPCE's market performance.
NeuroPace, Inc. (NPCE) reported first-quarter results, with analysts forecasting revenue growth to $65.5 million and adjusted EBITDA positivity for the full year. Q1 results and analyst forecasts for revenue growth and EBITDA positivity moderately influence NeuroPace's financial performance and investor sentiment.
13 May
NeuroPace, Inc. Q1 2026 earnings call summary covers financial results, operational updates, and future outlook for the neurotechnology company. Q1 2026 earnings call details major financial performance and strategic guidance likely to shift investor sentiment and company trajectory.
NeuroPace Inc (NPCE) Q1 2026 earnings call highlights revenue growth and strategic initiatives amid positive operational updates. Revenue growth and strategic advancements represent major positive drivers for NPCE's future financial performance and investor sentiment.
12 May
NeuroPace Q1 earnings call highlighted financial results, including revenue growth, RNS System expansions, and positive guidance amid epilepsy treatment advancements. Q1 earnings highlights detail revenue beats, product expansions, and raised guidance that significantly boost investor confidence and stock trajectory.
NeuroPace reported first quarter 2026 financial results and raised its full-year 2026 revenue guidance. Raising full-year revenue guidance signals strong performance and positively impacts future market trajectory.
NeuroPace, Inc. (NPCE) reported a Q1 net loss but beat revenue estimates. Q1 loss despite topping revenue estimates signals moderate financial impact with positive revenue momentum.
27 Apr
NeuroPace publishes 3-year Post-Approval Study (PAS) results in Neurology journal and schedules NAUTILUS presentation at AAN 2026, underscoring expanding clinical evidence leadership. Long-term PAS data publication in a top journal and major conference presentation validate product efficacy, likely enhancing investor sentiment and competitive positioning.
1 Apr
Shifting margin assumptions are rewriting the investment narrative for NeuroPace, Inc. (NPCE). Shifting margin assumptions significantly alter NeuroPace's investment narrative and market performance trajectory.
18 Mar
Analysts are refreshing valuation assumptions for NeuroPace (NPCE), shifting the company's investment narrative. Analysts' refreshed valuation assumptions moderately influence NeuroPace's market sentiment and trajectory.
10 Mar
Key catalysts are positioned to drive strong prospects for NeuroPace, Inc. (NPCE) stock in 2026. Outlined catalysts represent major strategic factors likely to significantly boost NPCE's trajectory and investor sentiment.
NeuroPace's RNS System powers growth through key drivers, positioning the company for strong performance in 2026. RNS System growth drivers signal major strategic positioning for NPCE's 2026 trajectory and investor sentiment.
NeuroPace's Seizure ID software upgrade and new indication for its RNS System could significantly expand patient eligibility and demand by improving seizure detection and treatment access. Seizure ID and new indication directly enhance core RNS product adoption and market potential, driving significant revenue growth.
4 Mar
NeuroPace Inc (NPCE) Q4 2025 earnings call highlights strong revenue growth and strategic initiatives. Strong revenue growth and strategic initiatives indicate significant positive impact on NPCE's future performance and investor sentiment.
3 Mar
NeuroPace (NPCE) conducted its Q4 2025 earnings call, reporting financial results, RNS System adoption growth, pipeline updates, and 2026 guidance. Quarterly earnings transcripts disclose key financial metrics, growth strategies, and guidance that drive stock volatility and long-term investor confidence.
NeuroPace Q4 earnings call highlighted financial results, including revenue growth, RNS System performance, patient expansion, and optimistic 2024 guidance amid pipeline advancements. Q4 earnings reveal strong revenue beats, expanded market access, and robust guidance signaling significant positive trajectory shifts.